This page shows what was measured, who it was measured in, and what that does not settle.
What Aripiprazole does in the body
Schizophrenia, bipolar disorder, depression that has not responded to an antidepressant alone, irritability in autism, and Tourette disorder
Most antipsychotics simply switch the dopamine receptor off. Aripiprazole sits in the same place but turns it partly on: where dopamine is over-active it acts as a brake, and where dopamine is under-active it supplies a weak signal of its own. That is why it causes far less of the flat, deadened feeling and none of the hormonal disruption that full blockers cause. It is also the reason it can push the brain's reward circuitry the wrong way in some people, producing compulsive gambling or shopping that stops when the drug is reduced or stopped.
What happened in people
A standardised mean difference of 0.43 against placebo for overall symptom change, ninth of fifteen ranked antipsychotics
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The recorded finding that sits closest to something a person would notice. Written into the record, not signed off, and it carries no population or interval.
That partial agonism makes aripiprazole more effective — the mechanism is genuinely novel and the pooled efficacy rank is ninth of fifteen
Where it acts
Mesolimbic and mesocortical dopamine synapses, and the mesolimbic reward circuitry where partial agonism is the proposed basis of the compulsive-behaviour signal
Kind of result
Symptoms and quality of life
Supervision
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
What the registries record it as
The substance registry classes this as chemical.
FDA substance registry · 82VFR53I78 · read 2026-08-29
Its recorded molecular formula is C23H27Cl2N3O2, weighing 448.39.
US prescribing information · d8183eaf-0093-4720-b8ed-20e570697511 · read 2026-08-30
Where each sentence above came from
No recorded sentence describes the change this makes in a way that stands on its own. The page opens with what it is taken for instead, and the recorded explanation follows below.
Shown as the opening line on this page.
A limit recorded against this substance. Not signed off as a reviewed claim.
The four opening statements run to 133 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Comparator
A comparator is whatever the treatment was measured against.
A picture of it, and where the picture fails
It is like the other runner in a race.
Where that stops being true. A race has one winner. A study can show both arms improved.
What people get wrong. Results are read without asking what the other group got. Beating nothing is not beating a treatment.
The control condition against which the experimental intervention is assessed.
Randomisation
Randomisation means chance decides who gets which treatment.
A picture of it, and where the picture fails
It is like a coin toss deciding the groups.
Where that stops being true. A coin toss is fair once. Fairness here comes from doing it for everyone.
What people get wrong. It is thought to make groups identical. It makes them similar on average, including on things nobody measured.
Allocation of participants to arms by a chance process, so that unmeasured factors are balanced in expectation.
Absolute difference
An absolute difference is how many more people in a hundred were affected.
A picture of it, and where the picture fails
It is like counting heads in two rooms of a hundred.
Where that stops being true. Heads are easy to count. Study results carry a margin of error too.
What people get wrong. It is confused with a percentage change, which can look far larger.
The arithmetic difference in event rates between arms.
Confidence interval
A confidence interval is the range the true answer is likely to sit in.
A picture of it, and where the picture fails
It is like a weather forecast giving a range rather than one number.
Where that stops being true. A forecast range covers tomorrow. This one covers what the study could resolve.
What people get wrong. The middle number is read as the answer. A range crossing zero means no change is still possible.
An interval estimate that would contain the true parameter in a stated proportion of repeated studies.
What happened in people◇Read from sources, not yet reviewed
What happened in people
Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.
Mean overall change in symptoms against placebo in acute schizophrenia, with all-cause discontinuation, weight gain, extrapyramidal effects, prolactin, QTc and sedation as secondary outcomes
✓ The study showed what it set out to show
Who was studied
Leucht 15-drug multiple-treatments meta-analysis
How many people
43049
Study design
Bayesian network meta-analysis of 212 blinded randomised trials
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Aripiprazole standardised mean difference 0.43 (95% CrI 0.34 to 0.52), ninth of fifteen; prolactin effect 0.22, the most favourable of the fifteen
Repeated elsewhere
Replicated
What this does not prove. Meeting one endpoint in one population does not carry to other goals or other people.
The limits of this study, and where it came from
Main limit. A novel mechanism did not translate into a higher efficacy rank. Aripiprazole placed below haloperidol, a 1967 first-generation drug.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral tablet, orally disintegrating tablet, oral solution, short-acting intramuscular injection, and long-acting intramuscular injections given monthly or every two months
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
Response and remission rates with adjunctive atypical antipsychotic versus placebo in antidepressant-resistant major depressive disorder
✓ The study showed what it set out to show
Who was studied
Nelson and Papakostas adjunctive antipsychotic meta-analysis
How many people
3480
Study design
Fixed-effects meta-analysis of 16 acute-phase randomised placebo-controlled trials
Compared against
A dummy treatment
Kind of result
A number that stands in for health
What was found
Response odds ratio 1.69 (95% CI 1.46 to 1.95, p<0.00001); remission odds ratio 2.00 (95% CI 1.69 to 2.37, p<0.00001)
Repeated elsewhere
Replicated
What this does not prove. Meeting one endpoint in one population does not carry to other goals or other people.
The limits of this study, and where it came from
Main limit. Discontinuation for adverse events had an odds ratio of 3.91 (95% CI 2.68 to 5.72) against placebo. Odds ratios did not differ between the individual atypical agents, so the evidence supports the class rather than aripiprazole in particular.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral tablet, orally disintegrating tablet, oral solution, short-acting intramuscular injection, and long-acting intramuscular injections given monthly or every two months
Interval reported. 95% CI 1
Written into the record, not signed off as a reviewed claim.
Three randomised placebo-controlled trials, 10 weeks
Compared against
A dummy treatment
Kind of result
A number that stands in for health
What was found
No indication was granted. The label records the safety experience from these studies and states that aripiprazole is not approved for dementia-related psychosis.
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. The programme is documented in the label's safety section rather than in an efficacy section, which is where trials that did not produce an indication end up.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral tablet, orally disintegrating tablet, oral solution, short-acting intramuscular injection, and long-acting intramuscular injections given monthly or every two months
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
All-cause death with atypical antipsychotic treatment versus placebo in Alzheimer disease and other dementia
✗ The study did not show it
Who was studied
Schneider dementia mortality meta-analysis
How many people
5110
Study design
Meta-analysis of 15 randomised placebo-controlled trials, nine unpublished
Compared against
A dummy treatment
Kind of result
Living longer, or avoiding a major event
What was found
Death in 3.5% on drug versus 2.3% on placebo; odds ratio 1.54 (95% CI 1.06 to 2.23, P = 0.02)
Repeated elsewhere
Replicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. Nine of the fifteen trials were unpublished at the time of the analysis and were obtained from sponsors. Three of the sixteen drug-placebo contrasts were aripiprazole.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral tablet, orally disintegrating tablet, oral solution, short-acting intramuscular injection, and long-acting intramuscular injections given monthly or every two months
Interval reported. 95% CI 1
Written into the record, not signed off as a reviewed claim.
RNAWiki holds 4 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What it changes in the body◇Read from sources, not yet reviewed
The path through the body
From what a person takes to what changes. A solid line is a step measured in people. A dashed line is a step nobody has measured that way.
Where a source records it acting
Brain: Dose-dependent D2 receptor occupancy indicating brain penetration in humans; efficacy could be mediated through partial agonist activity at D2 and 5-HT1A receptors and antagonist activity at 5-HT2A receptors
US prescribing information · 02a4af27-c83c-4166-950c-7a1cb12d198d · read 2026-08-27
Start
Aripiprazole
What a person takes: Oral tablet, orally disintegrating tablet, oral solution, short-acting intramuscular injection, and long-acting intramuscular injections given monthly or every two months.
The measurement behind this step
The 75-hour half-life makes the oral form unusually forgiving of a missed dose and means steady state takes about two weeks to reach, so early impressions of efficacy are unreliable. Abilify Maintena is given monthly and Abilify Asimtufii every two months. The Abilify MyCite kit, approved in 2017, paired the tablet with an ingestible sensor and a wearable patch; no label for it is currently listed on DailyMed.
Getting in
A daily tablet, or an injection lasting a month or two
Aripiprazole is usually a once-daily tablet. Long-acting injections given monthly or every other month exist for people for whom a daily tablet is the step that fails.
╌╌Described, with no measurement named. No measurement is named for this step, so it is drawn as an unconfirmed link.
The measurement behind this step
Oral bioavailability about 87%, terminal half-life roughly 75 hours for aripiprazole and 94 hours for its active metabolite dehydroaripiprazole, which is why steady state takes about two weeks and why missing a single tablet changes little. Clearance is through CYP2D6 and CYP3A4.
It crosses into the brain and the liver adds a second long-lived active molecule
The drug enters the brain readily, and the liver converts part of it into a related molecule that is also active and lasts even longer than the parent.
╌╌Described, with no measurement named. No measurement is named for this step, so it is drawn as an unconfirmed link.
The measurement behind this step
Dehydroaripiprazole shares the parent's D2 affinity and accounts for roughly 40% of the exposure at steady state. CYP2D6 poor metabolisers reach substantially higher concentrations, which is one of the few places in psychiatry where genotype has a documented dosing consequence in the label.
It occupies the dopamine receptor and turns it partly on
Aripiprazole binds the dopamine receptor as tightly as a blocker does, but instead of shutting the receptor down it produces a weak signal of its own. Against too much dopamine it acts as a brake; against too little it acts as a floor.
╌╌Described, with no measurement named. No measurement is named for this step, so it is drawn as an unconfirmed link.
The measurement behind this step
High-affinity partial agonism at D2 and D3 with low intrinsic activity, so it competes dopamine off the receptor and substitutes a submaximal signal. Striatal D2 occupancy above 80% is routinely reached without the extrapyramidal consequences a full antagonist would produce at that occupancy, which is the strongest clinical evidence that the partial agonism is real.
The same partial signal reaches the reward circuitry
The receptors aripiprazole partly activates are not only the ones involved in psychosis. The same receptors sit in the circuits that decide what feels rewarding, and in some people a weak persistent signal there produces compulsive gambling, shopping, eating or sexual behaviour.
╌╌Described, with no measurement named. No measurement is named for this step, so it is drawn as an unconfirmed link.
The measurement behind this step
D3-preferring partial agonism in mesolimbic reward pathways is the standard mechanistic account of the impulse-control signal, by analogy with the well-characterised effect of D3-preferring full agonists such as pramipexole in Parkinson disease. The label records that in some cases the urges stopped on reduction or discontinuation, which is the pattern a pharmacological cause predicts.
Symptoms fall modestly, hormones do not move, restlessness appears
On symptom scales aripiprazole performs in the middle of the field. What sets it apart is what stays normal: prolactin, weight and blood sugar. The characteristic complaint is an inner restlessness that makes it impossible to sit still.
╌╌Described, with no measurement named. No measurement is named for this step, so it is drawn as an unconfirmed link.
The measurement behind this step
Standardised mean difference against placebo of 0.43 (95% CrI 0.34 to 0.52) for overall symptom change, ninth of fifteen. Prolactin effect at the favourable extreme of the fifteen-drug range. Akathisia is the most frequent reason for discontinuation in the aripiprazole arms of the registration programme, and is attributed to partial agonism producing an intermediate dopaminergic state rather than to blockade.
No suggested links are held for this record, so nothing is hidden from this path.
What we know
The record describes 5 steps from taking it to an effect in a person.
How we know it
Each step names the study behind it in the technical detail beside it.
What this does not prove
A change inside the body is a reason to look. It is not a result in a person.
Why it matters
A reader can see exactly where the chain stops being measured in people.
What we still do not know
No reviewed claim binds any of these steps to a named population.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
Adults with schizophrenia and bipolar disorder; adults with depression, as an add-on; children and adolescents with autism-associated irritability or Tourette disorder.
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What the label states about particular groups
On pediatric, the label states: “Safety and effectiveness in pediatric patients with major depressive disorder or agitation associated with schizophrenia or bipolar mania have not been established.”
US prescribing information · d8183eaf-0093-4720-b8ed-20e570697511 · read 2026-08-30
On older people, the label states: “No dosage adjustment is recommended for elderly patients [see Boxed Warning , Warnings and Precautions (5.1) , and Clinical Pharmacology (12.3) ] .”
US prescribing information · d8183eaf-0093-4720-b8ed-20e570697511 · read 2026-08-30
On people who are pregnant, the label states: “Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to atypical antipsychotics, including aripiprazole, during pregnancy.”
US prescribing information · d8183eaf-0093-4720-b8ed-20e570697511 · read 2026-08-30
On people who are breastfeeding, the label states: “Risk Summary Limited data from published literature report the presence of aripiprazole in human breast milk, at relative infant doses ranging between 0.7% to 8.3% of the maternal weight-adjusted dosage.”
US prescribing information · d8183eaf-0093-4720-b8ed-20e570697511 · read 2026-08-30
Where the result stopped carrying
Three ten-week placebo-controlled trials in 938 elderly patients with Alzheimer psychosis produced no indication
Akathisia is the characteristic discontinuation reason in the aripiprazole arms, and it is a direct consequence of the mechanism rather than an incidental effect
The digital ingestion-tracking version approved in 2017 is no longer listed in the United States structured product label database
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (11)
It was studied for a different goal
The studies measured something else entirely. Nothing in this record points to this reason.
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Given by a clinician
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Oral tablet, orally disintegrating tablet, oral solution, short-acting intramuscular injection, and long-acting intramuscular injections given monthly or every two months
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form and route recorded on this substance.
No source is stored against this line.
Who oversees it
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Suppression classes recorded: S6, S9.
No source is stored against this line.
What is in the pack
The 75-hour half-life makes the oral form unusually forgiving of a missed dose and means steady state takes about two weeks to reach, so early impressions of efficacy are unreliable. Abilify Maintena is given monthly and Abilify Asimtufii every two months. The Abilify MyCite kit, approved in 2017, paired the tablet with an ingestible sensor and a wearable patch; no label for it is currently listed on DailyMed.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on how this is sold and what that means for what is in the pack.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
# Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
The recorded stepping schedule
What follows is the schedule printed on the label, recorded as it is written there. It is a record of what was done, not a recommendation.
US prescribing information · 02a4af27-c83c-4166-950c-7a1cb12d198d · read 2026-08-27
Days 1 to 2: Dosing initiated at 2 mg/day for 2 days — Label-stated schedule for Tourette's disorder, patients weighing 50 kg or more
US prescribing information · 02a4af27-c83c-4166-950c-7a1cb12d198d · read 2026-08-27
The following 5 days: Increased to 5 mg/day for 5 days — Label-stated schedule for Tourette's disorder, patients weighing 50 kg or more
US prescribing information · 02a4af27-c83c-4166-950c-7a1cb12d198d · read 2026-08-27
Day 8: Target dose of 10 mg/day on Day 8 — Label-stated target dose for Tourette's disorder, patients weighing 50 kg or more
US prescribing information · 02a4af27-c83c-4166-950c-7a1cb12d198d · read 2026-08-27
What it would be like to take◇Read from sources, not yet reviewed
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
·Worth asking a clinician aboutWritten into the record from the studies named on this page
The United States label carries boxed warnings for increased mortality in elderly patients with dementia-related psychosis and for suicidal thoughts and behaviours in children, adolescents and young adults. Section 5.7 covers pathological gambling and other compulsive behaviours. Akathisia is the most characteristic adverse effect. Weight gain and metabolic disturbance are markedly less than with olanzapine, and prolactin is not elevated. Orthostatic hypotension, seizures, leukopenia and neutropenia, tardive dyskinesia and neuroleptic malignant syndrome are all in the label.
Nobody counted how many people took this and were fine, so this cannot be turned into a rate.
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear◇Read from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Oral tablet, orally disintegrating tablet, oral solution, short-acting intramuscular injection, and long-acting intramuscular injections given monthly or every two months
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form used in the studies cited on this page.
No source is stored against this line.
What is sold
Abilify Maintena is given monthly and Abilify Asimtufii every two months. The Abilify MyCite kit, approved in 2017, paired the tablet with an ingestible sensor and a wearable patch; no label for it is currently listed on DailyMed.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on which forms are sold and how they compare.
No source is stored against this line.
What is recorded as being sold
328 products list this as an active ingredient in the United States drug directory. 328 of them contain it and nothing else.
FDA National Drug Code directory · 72865-156 · read 2026-08-29
They are sold as film, soluble, injection, powder, lyophilized, for suspension, extended release, injection, suspension, extended release, powder, solution and tablet, taken intramuscular and oral.
FDA National Drug Code directory · 72865-156 · read 2026-08-29
The regulator's established pharmacologic class for it is atypical antipsychotic [epc].
FDA National Drug Code directory · 72865-156 · read 2026-08-29
121 published labels name it as an active ingredient. 121 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · d8183eaf-0093-4720-b8ed-20e570697511 · read 2026-08-29
Those labels are classed as human prescription drug.
US prescribing information · d8183eaf-0093-4720-b8ed-20e570697511 · read 2026-08-29
Aripiprazole is tablets at Tablets: 2 mg, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg, recorded as prescription product; fda label in effect 2026-03-05 in the United States.
US prescribing information · 02a4af27-c83c-4166-950c-7a1cb12d198d · read 2026-08-27
Recorded price in US: 0.10341–0.16732 USD per one unit as the pricing file counts it — a tablet, capsule, patch or single item, across 177 priced products whose strengths and pack forms differ, as of 2026-08-26, paid by retail pharmacies buying the product, as surveyed by the Centers for Medicare & Medicaid Services. It is not a list price, an insurance price, or what anyone pays at a counter..
Recorded source · 2026-08-26 · read 2026-08-28
Recorded price in US: 0.31307 USD per one millilitre, across 7 priced products whose strengths and pack forms differ, as of 2026-08-26, paid by retail pharmacies buying the product, as surveyed by the Centers for Medicare & Medicaid Services. It is not a list price, an insurance price, or what anyone pays at a counter..
Recorded source · 2026-08-26 · read 2026-08-28
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
What it would be like to take◇Read from sources, not yet reviewed
What you could measure
This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.
Self-experiment planning is not offered for a prescription or clinician-supervised medicine. The questions below are for a clinician or pharmacist.
Questions worth asking
Which of the trials of Aripiprazole studied people like me?
What was measured, and for how long?
Was the result a laboratory value or a health outcome?
What would we watch for, and when would we stop?
Tracking can show whether something changed for you. It cannot show what caused it.
RNAWiki records evidence. It does not say whether this substance is right for you.
What is missing or unclear◇Read from sources, not yet reviewed
Claims that go past the evidence
Things said about this substance that sound reasonable, and the exact step that is missing between the evidence and the claim.
✗Goes past the evidence
That partial agonism makes aripiprazole more effective — the mechanism is genuinely novel and the pooled efficacy rank is ninth of fifteen
Why it sounds right. It follows from something real on this page: a body step, an animal result or a related finding.
The missing step. Nobody measured this in people for this use, or the study that did measure it did not show it.
What would change this
A study in people, for this exact use, measuring this exact thing, that a reviewer signs off.
RNAWiki has not yet published a reviewed conclusion for this use.
✗Goes past the evidence
That the adjunctive depression evidence is specific to aripiprazole — the pooled odds ratios did not differ between the atypical agents tested
Why it sounds right. It follows from something real on this page: a body step, an animal result or a related finding.
The missing step. Nobody measured this in people for this use, or the study that did measure it did not show it.
What would change this
A study in people, for this exact use, measuring this exact thing, that a reviewer signs off.
RNAWiki has not yet published a reviewed conclusion for this use.
✗Goes past the evidence
That an ingestible sensor improves adherence or outcomes — the 2017 approval covered detection of ingestion, and no label for that product is currently listed
Why it sounds right. It follows from something real on this page: a body step, an animal result or a related finding.
The missing step. Nobody measured this in people for this use, or the study that did measure it did not show it.
What would change this
A study in people, for this exact use, measuring this exact thing, that a reviewer signs off.
RNAWiki has not yet published a reviewed conclusion for this use.
✗Goes past the evidence
That it is safe in dementia-related psychosis because it lacks the metabolic profile of olanzapine — the mortality signal is a class finding with an odds ratio of 1.54
Why it sounds right. It follows from something real on this page: a body step, an animal result or a related finding.
The missing step. Nobody measured this in people for this use, or the study that did measure it did not show it.
What would change this
A study in people, for this exact use, measuring this exact thing, that a reviewer signs off.
RNAWiki has not yet published a reviewed conclusion for this use.
What is missing or unclear◇Read from sources, not yet reviewed
What nobody knows yet
Open questions, each with why it is open and what would close it.
Missing populations
Which groups were under-represented in the studies has not been recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing long-term data
No completed tested study window is recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
No reviewed conclusion
RNAWiki has not yet published a reviewed conclusion for this use.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing interaction studies
No interaction was found in the registers checked. Not finding one is not the same as showing there is none.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Formulation uncertainty
Several salts, forms or products of Aripiprazole are recorded. Results from one form may not transfer to another.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Mechanism not reviewed
No reviewed mechanism story exists for this substance.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
What happened in people◇Read from sources, not yet reviewed
Check any of this yourself
Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.
Every line above can be traced to the study named beside it. Follow the link and read it.
The only antipsychotic that lowers prolactin instead of raising it
In plain words
Every other antipsychotic in the fifteen-drug ranking pushed prolactin up. Aripiprazole was the one that pushed it down, which is why it is chosen when hormonal side effects matter, particularly in children and young adults.
What was measured
Standardised mean difference against placebo for prolactin change, weight gain and quality of life
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
In the Leucht multiple-treatments meta-analysis of 212 trials and 43,049 patients, standardised mean differences against placebo for prolactin increase ran from 0.22 for aripiprazole at one end to -1.30 for paliperidone at the other, with the sign convention such that aripiprazole was the only drug whose effect pointed away from prolactin elevation. On weight gain it also sat near the favourable end of the range, well away from olanzapine at -0.74. In the 2019 network meta-analysis of 32 drugs, aripiprazole produced the largest improvement in quality of life of the five drugs that significantly improved it (standardised mean difference -0.49, 95% CI -0.72 to -0.26).
Written into the record, not signed off as a reviewed claim
A new mechanism that produced a ninth-place drug
In plain words
Aripiprazole was the first antipsychotic to turn the dopamine receptor partly on rather than switching it off, and that was expected to be a step change. On pooled symptom reduction it came ninth of fifteen, below haloperidol.
What was measured
Standardised mean difference against placebo for overall symptom change
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
Standardised mean difference against placebo for overall symptom change was 0.43 (95% CrI 0.34 to 0.52) for aripiprazole, ranking it ninth of fifteen behind clozapine 0.88, amisulpride 0.66, olanzapine 0.59, risperidone 0.56, paliperidone 0.50, zotepine 0.49, haloperidol 0.45 and quetiapine 0.44. The authors of the analysis concluded that efficacy differences between antipsychotics are small but robust, and that the first- versus second-generation classification is not supported by the data. A mechanism that is genuinely novel and a drug that is measurably better are different claims, and only the first one is established for aripiprazole.
Written into the record, not signed off as a reviewed claim
The label warns that patients may start gambling and not notice
In plain words
Aripiprazole can produce sudden, intense urges to gamble, shop, eat or have sex. The label tells prescribers to ask about it specifically, because patients often do not recognise the behaviour as abnormal or connect it to a tablet.
What was measured
Post-marketing case reports of new-onset pathological gambling and other compulsive behaviours
Effect estimate
No reviewed effect estimate exists for this record.
Limits
This entry records a failure.
From the source
Section 5.7 of the United States prescribing information, headed "Pathological Gambling and Other Compulsive Behaviors", states that post-marketing case reports suggest patients can experience intense urges, particularly for gambling, and an inability to control them while taking aripiprazole; other compulsive urges reported less frequently include sexual urges, shopping, eating or binge eating. The label directs prescribers to ask patients or caregivers specifically about new or intense urges, notes that patients may not recognise the behaviours as abnormal, records that in some but not all cases the urges stopped when the amount was reduced or the drug was stopped, and warns that compulsive behaviours may result in harm to the patient and others if not recognised. The label also notes that impulse-control symptoms can be associated with the underlying disorder, which is a genuine confound and not a dismissal. The proposed mechanism is D3 and D2 partial agonism in mesolimbic reward circuitry, the same class of mechanism behind the compulsive behaviours seen with dopamine agonists used in Parkinson disease.
Source
United States prescribing information for aripiprazole, section 5.7, retrieved from the openFDA drug label endpoint; Drugs@FDA NDA 021436
Role in the trial
Not matched to a registered study
Identity check
no open identity hold
Audit mark
caution
Review state
Written into the record, not signed off as a reviewed claim
Adjunctive use in depression: response odds 1.69, dropout-for-harm odds 3.91
In plain words
Adding an antipsychotic to an antidepressant does help, on average, in depression that has not responded. The same pooled analysis shows people were nearly four times as likely to stop because of side effects.
What was measured
That aripiprazole specifically is the right add-on for resistant depression — the pooled analysis found no difference between the atypical agents, so the evidence supports the class rather than the molecule
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
Nelson and Papakostas pooled sixteen acute-phase, parallel-group, double-blind randomised trials with 3,480 patients who had non-psychotic unipolar major depressive disorder resistant to prior antidepressant treatment. Adjunctive atypical antipsychotics beat placebo for response (odds ratio 1.69, 95% CI 1.46 to 1.95, z=7.00, p<0.00001) and for remission (odds ratio 2.00, 95% CI 1.69 to 2.37, z=8.03, p<0.00001). Mean odds ratios did not differ between the individual atypical agents and were not affected by trial duration or by how treatment resistance was established. Discontinuation for adverse events was substantially higher on drug than on placebo (odds ratio 3.91, 95% CI 2.68 to 5.72, z=7.05, p<0.00001). The benefit is real, class-wide and modest; presenting the response odds ratio without the discontinuation odds ratio describes half of the same analysis.
Written into the record, not signed off as a reviewed claim
A 938-patient Alzheimer psychosis programme that never produced an indication
In plain words
Three ten-week placebo-controlled trials tested aripiprazole in 938 elderly people with psychosis in Alzheimer disease. The drug is still not approved for it, and the label carries a boxed warning against using antipsychotics in that population.
What was measured
Mortality odds ratio for atypical antipsychotics against placebo in randomised dementia trials
Effect estimate
No reviewed effect estimate exists for this record.
Limits
This entry records a failure.
From the source
The United States prescribing information records three ten-week placebo-controlled studies of aripiprazole in elderly patients with psychosis associated with Alzheimer disease, with 938 participants, mean age 82.4 years, range 56 to 99. No indication resulted. Section 5.1 states that elderly patients with dementia-related psychosis treated with antipsychotic drugs are at increased risk of death and that aripiprazole is not approved for dementia-related psychosis. The pooled evidence behind that warning is fifteen randomised placebo-controlled trials of atypical antipsychotics in dementia, three of the sixteen drug-placebo contrasts contributed by aripiprazole, with death in 3.5% on drug against 2.3% on placebo, odds ratio 1.54 (95% CI 1.06 to 2.23, P=0.02).
Written into the record, not signed off as a reviewed claim
The digital pill that was approved in 2017 no longer has a listed label
In plain words
In 2017 the FDA approved a version of aripiprazole with a sensor baked into the tablet that reports to a phone when it has been swallowed. As of August 2026 no label for that product is listed on the United States drug label database.
What was measured
That an ingestion sensor improves outcomes — the approval covered detection of ingestion, and the product is no longer listed in the label database
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
ABILIFY MYCITE KIT, NDA 207202, sponsored by Otsuka, was approved on 13 November 2017 and combines aripiprazole tablets carrying an ingestible event marker with a wearable patch and a smartphone application. It was widely covered as the first digital medicine approved in the United States. A query of the DailyMed structured product label database in August 2026 returns thirteen ABILIFY labels and none for MYCITE, and the openFDA label endpoint returns no match for the brand name. The Drugs@FDA application record for NDA 207202 remains, listing 2 mg, 15 mg and 30 mg kit products. What was licensed was a tracking system, not a better antipsychotic: the aripiprazole in the kit is the same molecule with the same efficacy figures as the generic tablet.
Source
Drugs@FDA NDA 207202 (ABILIFY MYCITE KIT), original approval 13 November 2017; DailyMed and openFDA label queries, August 2026
Role in the trial
Not matched to a registered study
Identity check
no open identity hold
Audit mark
contested
Review state
Written into the record, not signed off as a reviewed claim
Its co-promotion was part of a US$515 million settlement in 2007
In plain words
In 2007 Bristol-Myers Squibb, which co-promoted aripiprazole, agreed to pay more than half a billion dollars to resolve United States allegations about illegal drug marketing and pricing.
What was measured
That paediatric and elderly prescribing of aripiprazole before 2009 followed the evidence — some of it followed promotion that was found unlawful
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
The United States Department of Justice announced in September 2007 that Bristol-Myers Squibb would pay more than US$515 million to resolve allegations of illegal drug marketing and pricing, with the conduct at issue including promotion of Abilify for uses in paediatric patients and in dementia-related psychosis that were not approved at the time. The paediatric indications aripiprazole now holds — autism-associated irritability from 2009, Tourette disorder from 2014 — were granted after trials were run and reviewed; the promotion that preceded them was not supported by that review. The sequence matters for reading prescribing data from that period.
Source
United States Department of Justice, Office of Public Affairs, 28 September 2007: "Bristol-Myers Squibb to Pay More Than $515 Million to Resolve Allegations of Illegal Drug Marketing and Pricing"
Role in the trial
Not matched to a registered study
Identity check
no open identity hold
Audit mark
contested
Review state
Written into the record, not signed off as a reviewed claim
How many documents were read
118 documents were read for this substance.
RNAWiki source record
104 of them state the same bioavailability, and they agree.
RNAWiki source record
104 of them state the same tMax, and they agree.
RNAWiki source record
Where else this substance is registered
FDA substance identifier (UNII)
82VFR53I78
CAS registry number
129722-12-9
PubChem compound
60795
RxNorm concept
89013
Checks this page had to pass
✓ Passed
Identity resolved
no open identity hold
✓ Passed
No unresolved merge across substance families
no quarantine open
✓ Passed
Every public sentence names a source
The opening statement carries the origin: Written into the record, not signed off.
✗ Not passed
Trial roles classified for highlighted evidence
No registered study is classified as testing this substance.
✓ Passed
No internal keys in reader text
enforced by the copy-contract test over the rendered page
✓ Passed
Safety mode resolved
Suppression classes recorded: S6, S9.
✓ Passed
Canonical metadata present
slug and display name present
What is missing or unclear◇Read from sources, not yet reviewed
How this medicine reached us
Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.
What the approval register records
51 approved applications cover products containing this substance. The earliest was NDA021436, approved 20021115 to OTSUKA.
This order is fixed in code and does not count clicks or time on the page.
What is not here
7 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
What was measured, goal by goal — found nothing in the sources checked.
How close this is to real life — found nothing in the sources checked.
Felt, measured, or meaningful — found nothing in the sources checked.
How long anything takes — found nothing in the sources checked.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
The older medicine-wide conclusion held in this record
Written for a clinical reader, and about the medicine as a whole rather than about one indication, population and set of trials. RNAWiki does not treat it as a programme conclusion and no reviewer has signed it off in that form. It is here word for word because it is what the record holds.
The first dopamine partial agonist to reach market, which produced almost no prolactin elevation and much less weight gain than olanzapine, ranked ninth of fifteen antipsychotics on pooled symptom reduction, and is the only drug in this class whose United States label carries a dedicated section warning that patients may develop uncontrollable urges to gamble, shop, eat or have sex.
Recorded evidence blocks (10)
Q2
On the Aripiprazole label: indicated for what?
"1 INDICATIONS & USAGE Aripiprazole tablets are indicated for the treatment of: Schizophrenia Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Disorder Adjunctive Treatment of Major Depressive Disorder Irritability Associated with Autistic Disorder Treatment of Tourette’s Disorder Aripiprazole…": indications and usage on Aripiprazole's label. DailyMed label · 1d593ada-256d-4dec-9a26-2a6a67d97205 · 2026-07-31
Q3
318 registered trials of Aripiprazole — at which phases?
Registered studies posting no result
195 of 318
318 registered studies of Aripiprazole: 117 phase4, 105 phase3, 33 na, 31 phase2, 28 phase1, 13 na or unstated, 1 early phase1. CLINICALTRIALS_SNAPSHOT · 2026-09-01
587 with a PubMed record
Show the evidence
phase4
117
phase3
105
na
33
phase2
31
phase1
28
na or unstated
13
8 more recorded rows
early phase1
1
completed
230
terminated
34
unknown
31
withdrawn
11
not yet recruiting
6
recruiting
5
active not recruiting
1
recorded 2026-09-01 · last checked 2026-09-04
Q4
39 of Aripiprazole's trials stopped: safety, futility/efficacy, accrual/recruitment, funding/business, other?
safety (7), futility/efficacy (2), accrual/recruitment (16), funding/business (8) and other (6): Aripiprazole's stop wording, clustered. CLINICALTRIALS_SNAPSHOT · 2026-09-01
"The study was terminated due to low enrollment."; 39 of 318 registered studies
Show the evidence
Trial
NCT00169949
terminated; "The study was terminated due to low enrollment."
NCT00209027
terminated; "difficulty with technical aspect of fMRI, resources to complete the study ran out"
NCT00211302
terminated; "Enrollment too difficult"
NCT00211380
terminated; "Recruitment was too difficult"
NCT00276978
withdrawn; "Initiation of study was stopped due to administrative reasons before first subject was enrolled."
NCT00279409
terminated; "Recruitment Rate too slow"
14 further recorded trials
NCT00288353
terminated; "unable to secure additional funding"
NCT00508157
terminated; "Slow Accrual"
NCT00592683
terminated; "Supply Omega-3 Fatty Acids expired and supplier no longer made same composition."
NCT00665444
terminated; "The study was terminated by the sponser due to low study enrollment."
NCT00712270
terminated; "Study terminated due to failure to meet sufficient enrollment for valid analysis"
NCT00728312
withdrawn; "PI left the VA."
NCT00746252
terminated; "Due low rate of participation and lack of funding"
NCT00857818
terminated; "Slow Accrual"
NCT00910780
withdrawn; "Study was not funded."
NCT01111539
terminated; "The study was terminated early due to Sponsor decision, closure of this combination therapy program is unrelated to any safety issues, no signals of concern."
NCT01111552
terminated; "The study was terminated early due to Sponsor decision, closure of this combination therapy program is unrelated to any safety issues, no signals of concern."
NCT01111565
terminated; "The study was terminated early due to Sponsor decision, closure of this combination therapy program is unrelated to any safety issues, no signals of concern."
NCT01122927
terminated; "The trial was terminated early as the objective of the Aripiprazole Pediatric Investigational Plan was met and provided 2 years of safety data."
NCT01123707
terminated; "The study was terminated early due to Sponsor decision; no safety issues."
recorded 2026-09-01 · last checked 2026-09-04
Q5
Human studies of Aripiprazole used Aripiprazole tablet, 10 mg — over how long?
studies of Aripiprazole used the recorded amount. ClinicalTrials.gov · 2026-09-01
20 recorded entries; human; tablet, orally; also "Aripiprazole tablet, 10 mg", "Aripiprazole tablet, 30 mg", "Escitalopram on days -7 to day 14; Aripiprazole dosed starting Day 1 to day 14: 3 days at 10 mg, 4 days at 15 mg and 7…"
Show the evidence
human
NCT00102063
tablet; Aripiprazole tablet, 10 mg
NCT00102063
tablet; Aripiprazole tablet, 30 mg
NCT00361790
Escitalopram on days -7 to day 14; Aripiprazole dosed starting Day 1 to day 14: 3 days at 10 mg, 4 days at 15 mg and 7 days at 20 mg
NCT00362271
Venlafaxine on Day -4 to day 14, Aripiprazole dosed starting on Day 1: 3 days at 10 mg, 4 days at 1 mg and 7 days at 20 mg.
NCT00683852
Aripiprazole 5mg
NCT00683852
Aripiprazole 2mg
14 more recorded rows
humanNCT00706654
Aripiprazole depot 300 or 400 mg
humanNCT00706654
orally; Aripiprazole 10-30 mg orally
humanNCT00706654
Aripiprazole depot 25 or 50 mg
humanNCT00884884
Topiramate 100, Aripiprazole 15mg
humanNCT00884884
Topiramate 200, Aripiprazole 7.5mg
humanNCT01942161
Aripiprazole Low (2 mg/day)
humanNCT01942161
Aripiprazole Mid (6 - 12 mg/day)
humanNCT01942161
Aripiprazole High (24 - 30 mg/day)
humanNCT02501109
tablet; Abilify® 10 mg tablet
humanNCT02697045
Aripiprazole 400mg LAI
humanNCT04765085
Aripiprazole 5Mg Oral Tablet
humanNCT05103410
ARIPiprazole 30 MG
humanNCT05532254
tablet; Aripiprazole 10 mg tablet
humanNCT05766540
Aripiprazole 10 MG
recorded 2026-09-01 · last checked 2026-09-04
Q6
Aripiprazole's half-life is 75 hours — which schedules were studied?
75 hours; The mean elimination half-lives are about 75 hours and 94 hours for aripiprazole and dehydro-aripiprazole, respectively.
tmaxpharmacokinetics
3 hours; Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
bioavailabilitypharmacokinetics
87 %; Absorption Aripiprazole is well absorbed after administration of the tablet, with peak plasma concentrations occurring within 3 hours to 5 hours; the absolute oral bioavailability of the tablet formulation is 87%.
metabolismpharmacokinetics
Elimination of aripiprazole is mainly through hepatic metabolism involving two P450 isozymes, CYP2D6 and CYP3A4.
recorded 2026-07-31 · last checked 2026-09-04
Q7
Which 126 trials of Aripiprazole posted no result?
Posted no result
126 of 126 completed trials
Registrations
NCT00036101, NCT00036127, NCT00036361, NCT00041678, NCT00046384 and NCT00036348, and 120 more
Completion dates
oldest 2003-01; newest 2024-07-31
Show the evidence
Trial
NCT00036101
2003-01
NCT00036127
2003-01
NCT00036361
2003-01
NCT00041678
2003-03
NCT00046384
2003-04
NCT00036348
2003-06
14 further recorded trials
NCT00036114
2003-08
NCT00712686
2003-12
NCT00080327
2004-09
NCT00095810
2004-09
NCT00283179
2004-12
NCT00095719
2005-03
NCT00101569
2005-03
NCT00634348
2005-03
NCT00082199
2005-08
NCT00237913
2005-08
NCT00167817
2005-09
NCT00222833
2005-12
NCT00329810
2006-03
NCT00440713
2006-03
Q8
At the median, Aripiprazole's trials enrolled 90 people — anything larger?
Median enrolment
90
Largest enrolment
1037352
Registered trials counted
310
Q9
What do 9047 spontaneous reports say about Aripiprazole — and not say?
These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.
Aripiprazole appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 9047 reaction mentions were counted: weight increased 1427; suicide attempt 1049; akathisia 957; psychotic disorder 907. FAERS via Open Targets · CHEMBL1112 · 2026-06-24
Show the evidence
weight increased
1427
suicide attempt
1049
akathisia
957
psychotic disorder
907
tardive dyskinesia
868
anxiety
811
4 more recorded rows
tremor
811
dystonia
765
dyskinesia
726
extrapyramidal disorder
726
recorded 2026-06-24 · last checked 2026-09-04
Q10
Which 10 reactions does Aripiprazole's label not list?
Dosage adjustment due to drug interactions ( 7.1 ): Factors Dosage Adjustments for Aripiprazole Known CYP2D6 Poor Metabolizers Administer half of usual dose Known CYP2D6 Poor Metabolizers and strong CYP3A4 inhibitors Administer a quarter of usual dose Strong CYP2D6 or CYP3A4 inhibitors Administer half of usual dose Strong CYP2D6 and CYP3A4 inhibitors Administer a quarter of usual dose Strong…
drug_interactions
Reduce the aripiprazole dosage when administered concomitantly with a strong CYP3A4 inhibitor or a strong CYP2D6 inhibitor [see Dosage and Administration (2.6)].
drug_interactions
Strong CYP3A4 Inducers (e.g., carbamazepine, rifampin) Concomitant use of aripiprazole and carbamazepine decreased the exposure of aripiprazole compared to the use of aripiprazole alone [see Clinical Pharmacology (12.3)] .
drug_interactions
Increase the aripiprazole dosage when administered concomitantly with a strong CYP3A4 inducer [see Dosage and Administration (2.6)].
drug_interactions
In addition, no dosage adjustment is necessary for substrates of CYP2D6 (e.g., dextromethorphan, fluoxetine, paroxetine, or venlafaxine), CYP2C9 (e.g., warfarin), CYP2C19 (e.g., omeprazole, warfarin, escitalopram), or CYP3A4 (e.g., dextromethorphan) when coadministered with aripiprazole.
pharmacokinetics
Elimination of aripiprazole is mainly through hepatic metabolism involving two P450 isozymes, CYP2D6 and CYP3A4.
2 more recorded rows
Interaction statementpharmacokinetics
For CYP2D6 poor metabolizers, the mean elimination half-life for aripiprazole is about 146 hours.
Interaction statementpharmacokinetics
Based on in vitro studies, CYP3A4 and CYP2D6 enzymes are responsible for dehydrogenation and hydroxylation of aripiprazole, and N-dealkylation is catalyzed by CYP3A4.
ChEMBL 37 — CC BY-SA 3.0 Unported · ChEMBL ATC CC BY-SA · ClinicalTrials.gov — US Government work · Open Targets 26.06 — CC0 · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work
✗ required summary fields resolved: 4 required field(s) not terminal: Why people use it, Best-supported result, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 6 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.